Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures and neuropsychiatric disorders for both hospital and home settings.
*Delayed quote courtesy of Google Finance.
View Stock Information
Lookup Date :
- Dec 13, 2018 Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
- Dec 11, 2018 Marinus Pharmaceuticals Announces Public Offering of Common Stock